Recombinant human adenovirus‑p53 improves the outcome of mid‑late stage pancreatic cancer via arterial infusion

  • Authors:
    • Jinggang Mo
    • Meihua Lin
    • Bin He
    • Kai Tan
    • Chong Jin
    • Hao Jiang
    • Xuefeng Pan
    • Weidong Lin
  • View Affiliations

  • Published online on: September 25, 2017     https://doi.org/10.3892/ol.2017.7058
  • Pages:6829-6832
Metrics: PDF 0 views | HTML 0 views
0

Abstract

The present study aimed to investigate the therapeutic efficacy and clinical value of recombinant human adenovirus‑p53 (rAd‑p53) perfusion via the pancreatic artery for the treatment of mid‑late stage pancreatic cancer. rAd‑p53 (2x1012 virus particles) in 6 ml normal saline was pushed (intravenous bolus) into the gastroduodenal and superior pancreaticoduodenal arteries via interventional superselection, with the catheter retained for subsequent drug administration at a 3‑day interval for 4 cycles. Tumor changes in all patients were observed to evaluate tumor response by computed tomography (CT) at 2, 8 and 16 weeks post‑treatment. The following improvements were noted in the 23‑patient cohort: A total of 73.9% (17/23) of patients demonstrated significant tumor shrinkage (>20%); the symptoms of abdominal and back pain were relieved in 15 patients; the survival time was >12 months in 1 patient and >6 months in 14 patients; the patient's general condition, including appetite, was improved in 13 patients; body weight was increased in 9 patients; jaundice was attenuated in 12 patients; and ascites subsided in 10 patients. However, the therapeutic outcome was poor in 2 patients whose tumors size did not show significant change after treatment as detected by CT. These 2 patients succumbed within 6 months. In conclusion, rAd‑p53 perfusion via the pancreatic artery is a safe and minimally invasive option for the treatment of mid‑late stage pancreatic cancer.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Mo, J., Lin, M., He, B., Tan, K., Jin, C., Jiang, H. ... Lin, W. (2017). Recombinant human adenovirus‑p53 improves the outcome of mid‑late stage pancreatic cancer via arterial infusion. Oncology Letters, 14, 6829-6832. https://doi.org/10.3892/ol.2017.7058
MLA
Mo, J., Lin, M., He, B., Tan, K., Jin, C., Jiang, H., Pan, X., Lin, W."Recombinant human adenovirus‑p53 improves the outcome of mid‑late stage pancreatic cancer via arterial infusion". Oncology Letters 14.6 (2017): 6829-6832.
Chicago
Mo, J., Lin, M., He, B., Tan, K., Jin, C., Jiang, H., Pan, X., Lin, W."Recombinant human adenovirus‑p53 improves the outcome of mid‑late stage pancreatic cancer via arterial infusion". Oncology Letters 14, no. 6 (2017): 6829-6832. https://doi.org/10.3892/ol.2017.7058